Oliver Dorigo, MD, PhD, discusses the clinical efficacy of maveropepimut-S in patients with recurrent ovarian cancer.
Oliver Dorigo, MD, PhD
Advertisement
Articles by Oliver Dorigo, MD, PhD
Oliver Dorigo, MD, PhD, associate professor of Obstetrics and Gynecology, Stanford University Medical Center, Stanford Medicine, discusses the use of immunotherapy in the treatment of patients with ovarian cancer.
Advertisement
Latest Updated Articles
Dr Dorigo on the Clinical Benefit with Maveropepimut-S in Recurrent Ovarian CancerPublished: March 27th 2023 | Updated:
Dr. Dorigo on Immunotherapy in Ovarian CancerPublished: November 13th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5